orphan drug

Thanks to the legal basis that now exists we are able to fund these orphan drugs.

This question of orphan drugs leads us to the whole matter of public health.

She said that in several cases, even when new orphan drugs were approved and marketed, companies could not meet the demand for them.

It has been granted orphan drug status in Europe.

The profits some companies make on "orphan drugs" are again the focus of an effort by Congress to rein them in.

It took the Commission long enough to present a proposal for a European orphan drug act.

As a result, orphan drugs are among the biotechnology industry's biggest moneymakers.

The orphan drug movement began in the United States.

This is known as the "orphan drug" problem.

And Congressional committees have concluded that the same holds true for all of the orphan drugs now on the books.

Japan and the United States have awarded orphan drugs special status.

As a consequence, it's an extremely expensive "orphan drug" produced with government assistance.

Currently, 350 orphan drugs have been approved for sale in the US.

Drugs used to treat such conditions are considered to be "orphan drugs."

Congress is considering modifying the orphan drug law to prevent such situations from occurring.

Moreover, it is difficult to determine how many of the orphan drugs under development would have been researched even without the incentives.

Orphan drug status, however, gives a manufacturer specific financial incentives to develop and provide such medications.

Most of the work on orphan drugs is done by small- to medium-sized biotechnology companies created to develop new products.

In large part because of the government incentives, several so-called orphan drugs now make their manufacturers more than $1 billion a year.

Orphan drug designation means that the sponsor qualifies for certain benefits, such as reduced taxes, from the federal government.

Orphan drug status is a special incentive given to companies that are first to win approval for a drug used on fewer than 200,000 people.

Such a drug may be designated an "orphan drug" if fewer than 200,000 people needed it when the company received the designation.

One particular success is on the issue of the budget line associated with the approval of orphan drugs by the medicines agency.

"Because of me and my policies, dozens of so-called orphan drugs have found their way to those who need them, usually without cost.

Orphanet - The portal for rare diseases and orphan drug.